{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:43:03Z","timestamp":1792546983475,"version":"4.5.0"},"reference-count":178,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RG194194"],"award-info":[{"award-number":["RG194194"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R01AG057531-03"],"award-info":[{"award-number":["5R01AG057531-03"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL148167"],"award-info":[{"award-number":["R01HL148167"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1196150"],"award-info":[{"award-number":["1196150"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2006765"],"award-info":[{"award-number":["2006765"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jacc.2025.09.1502","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:30:41Z","timestamp":1767713441000},"page":"77-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Current and Emerging Therapeutic Approaches for Vascular Cognitive Impairment and Dementia"],"prefix":"10.1016","volume":"87","author":[{"given":"Louise S.","family":"Goodall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9595-3220","authenticated-orcid":false,"given":"Perminder S.","family":"Sachdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip B.","family":"Gorelick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C.","family":"Kovacic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Samaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jacc.2025.09.1502_bib1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jacc.2025.11.008","article-title":"Vascular cognitive impairment and dementia (VCID): clinical features, neuropathology, and biomarkers","volume":"87","author":"Sachdev","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1206572","article-title":"Current and future therapeutic strategies for Alzheimer's disease: an overview of drug development bottlenecks","volume":"15","author":"Peng","year":"2023","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.jacc.2025.09.1502_bib3","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","article-title":"Dementia prevention, intervention, and care: 2024 report of the Lancet Standing Commission","volume":"404","author":"Livingston","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.09.1502_bib5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1590\/S0004-282X2010000200006","article-title":"Limitations in differentiating vascular dementia from Alzheimer\u2019s disease with brief cognitive tests","volume":"68","author":"Matioli","year":"2010","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.jacc.2025.09.1502_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fnagi.2017.00047","article-title":"White matter damage in the cholinergic system contributes to cognitive impairment in subcortical vascular cognitive impairment, no dementia","volume":"9","author":"Liu","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.jacc.2025.09.1502_bib7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/aps.2009.82","article-title":"Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment","volume":"30","author":"Wang","year":"2009","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jacc.2025.09.1502_bib8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0022-510X(00)00300-2","article-title":"Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial","volume":"175","author":"Pantoni","year":"2000","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jacc.2025.09.1502_bib9","article-title":"Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD) 5: guidelines for management of vascular cognitive impairment","volume":"6","author":"Smith","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.jacc.2025.09.1502_bib10","series-title":"Neurobiology of Alzheimer\u2019s Disease","author":"Dawbarn","year":"2001"},{"key":"10.1016\/j.jacc.2025.09.1502_bib11","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1161\/STROKEAHA.109.570077","article-title":"Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size","volume":"41","author":"Roman","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.09.1502_bib12","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/01.STR.0000091396.95360.E1","article-title":"Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial","volume":"34","author":"Black","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.09.1502_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/01.WNL.0000078943.50032.FC","article-title":"Donepezil in vascular dementia: a randomized, placebo-controlled study","volume":"61","author":"Wilkinson","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2025.09.1502_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/1567205019666220120112301","article-title":"Comparative efficacy and acceptability of cholinesterase inhibitors and memantine based on dosage in patients with vascular cognitive impairment: a network meta-analysis","volume":"19","author":"Shi","year":"2022","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.jacc.2025.09.1502_bib15","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1002\/alz.13770","article-title":"Minimal clinically important difference in Alzheimer\u2019s disease: rapid review","volume":"20","author":"Muir","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.jacc.2025.09.1502_bib16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2002.tb00221.x","article-title":"Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer\u2019s disease","volume":"8","author":"Lilienfeld","year":"2002","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.jacc.2025.09.1502_bib17","article-title":"Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis","volume":"2","author":"Battle","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2025.09.1502_bib18","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1185\/03007990802328142","article-title":"Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the Vantage study","volume":"24","author":"Ballard","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacc.2025.09.1502_bib19","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2147\/NDT.S2221","article-title":"Rivastigmine in Chinese patients with subcortical vascular dementia","volume":"3","author":"Mok","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.jacc.2025.09.1502_bib20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1600-0404.2009.01263.x","article-title":"A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease","volume":"121","author":"Narasimhalu","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jacc.2025.09.1502_bib21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00004850-200211000-00005","article-title":"A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500)","volume":"17","author":"Wilcock","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib22","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1161\/01.STR.0000020094.08790.49","article-title":"Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300)","volume":"33","author":"Orgogozo","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.09.1502_bib23","first-page":"13","article-title":"The efficay of cebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double-blind, placebo-controlled trial","volume":"9","author":"Xiao","year":"1999","journal-title":"Hong Kong J Psychiatry"},{"key":"10.1016\/j.jacc.2025.09.1502_bib24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.01.012","article-title":"Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial","volume":"20","author":"Guekht","year":"2011","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jacc.2025.09.1502_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jalz.2015.04.010","article-title":"The effects of dl-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease: a multicentre, randomized, double-blind, placebo-controlled trial","volume":"12","author":"Jia","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.jacc.2025.09.1502_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5012341","article-title":"A review of recent advances in neuroprotective potential of 3-n-butylphthalide and its derivatives","volume":"2016","author":"Abdoulaye","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jacc.2025.09.1502_bib27","first-page":"8773","article-title":"Efficacy of butylphthalide soft capsules in patients with vascular dementia and the relevant antioxidative mechanism","volume":"12","author":"Wang","year":"2018","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib28","first-page":"7773","article-title":"Effects of butylphthalide combined with naofukang on cognitive function and the expression of serum neurotrophic factor in patients with vascular dementia","volume":"13","author":"Chen","year":"2020","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.29271\/jcpsp.2020.01.23","article-title":"Effects of butyphthalide combined with idebenone on inflammatory cytokines and vascular endothelial functions of patients with vascular dementia","volume":"30","author":"Qi","year":"2020","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.jacc.2025.09.1502_bib30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2318-10-14","article-title":"Effects of ginkgo biloba in dementia: systematic review and meta-analysis","volume":"10","author":"Weinmann","year":"2010","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.jacc.2025.09.1502_bib31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0022-510X(00)00301-4","article-title":"The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia","volume":"175","author":"Pantoni","year":"2000","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jacc.2025.09.1502_bib32","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1590\/0004-282X20140055","article-title":"Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study)","volume":"72","author":"Caramelli","year":"2014","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.jacc.2025.09.1502_bib33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1590\/1980-57642015dn93000004","article-title":"Neuropsychiatric symptoms in vascular cognitive impairment: a systematic review","volume":"9","author":"Tiel","year":"2015","journal-title":"Dement Neuropsychol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib34","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1017\/S1041610218001679","article-title":"A systematic review of non-pharmacological interventions for BPSD in nursing home residents with dementia: from a perspective of ergonomics","volume":"31","author":"Wang","year":"2019","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.jacc.2025.09.1502_bib35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1192\/bjp.bp.112.118307","article-title":"Late-life depression and risk of vascular dementia and Alzheimer\u2019s disease: systematic review and meta-analysis of community-based cohort studies","volume":"202","author":"Diniz","year":"2013","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jacc.2025.09.1502_bib36","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17r11772","article-title":"Meta-analysis of the prevalence of major depressive disorder among older adults with dementia","volume":"79","author":"Asmer","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jacc.2025.09.1502_bib37","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1176\/appi.ajp.2009.09020280","article-title":"Association of depressed mood and mortality in older adults with and without cognitive impairment in a prospective naturalistic study","volume":"167","author":"Lavretsky","year":"2010","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jacc.2025.09.1502_bib38","article-title":"Antidepressants for treating depression in dementia","volume":"8","author":"Dudas","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2025.09.1502_bib39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000102570","article-title":"A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia","volume":"24","author":"de Vasconcelos Cunha","year":"2007","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.jacc.2025.09.1502_bib40","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/gerona\/gls230","article-title":"Depression treatment selectively modifies arterial stiffness in older participants","volume":"68","author":"Scuteri","year":"2013","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jacc.2025.09.1502_bib41","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/archgenpsychiatry.2009.204","article-title":"Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial","volume":"67","author":"Sheline","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jacc.2025.09.1502_bib42","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jad.2020.02.005","article-title":"Comparative efficacy of nine antidepressants in treating Chinese patients with post-stroke depression: a network meta-analysis","volume":"266","author":"Li","year":"2020","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jacc.2025.09.1502_bib43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/156720507779939805","article-title":"Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study","volume":"4","author":"Zhong","year":"2007","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.jacc.2025.09.1502_bib44","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/01.JGP.0000196628.12010.35","article-title":"Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial","volume":"14","author":"Tariot","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jacc.2025.09.1502_bib45","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s002130050064","article-title":"Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment","volume":"148","author":"Allain","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jacc.2025.09.1502_bib46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4088\/JCP.v60n0207","article-title":"Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial","volume":"60","author":"Katz","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jacc.2025.09.1502_bib47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4088\/JCP.v64n0205","article-title":"A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia","volume":"64","author":"Brodaty","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jacc.2025.09.1502_bib48","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00019442-200307000-00004","article-title":"Psychosis of Alzheimer disease: validity of the construct and response to risperidone","volume":"11","author":"Schneider","year":"2003","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jacc.2025.09.1502_bib49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/gps.930100208","article-title":"A randomized, placebo-controlled trial of thiothixine in agitated, demented nursing home patients","volume":"10","author":"Finkel","year":"1995","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jacc.2025.09.1502_bib50","article-title":"Antipsychotics for agitation and psychosis in people with Alzheimer\u2019s disease and vascular dementia","volume":"12","author":"Muhlbauer","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2025.09.1502_bib51","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1176\/appi.ajp.20220508","article-title":"Dementia is more than memory loss: neuropsychiatric symptoms of dementia and their nonpharmacological and pharmacological management","volume":"179","author":"Tampi","year":"2022","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jacc.2025.09.1502_bib52","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/23969873211012132","article-title":"ESO guideline on covert cerebral small vessel disease","volume":"6","author":"Wardlaw","year":"2021","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.jacc.2025.09.1502_bib53","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/gerona\/glr232","article-title":"Occurrence of hypotension in older participants: which 24-hour ABPM parameter better correlates with it?","volume":"67","author":"Scuteri","year":"2012","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jacc.2025.09.1502_bib54","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jamainternmed.2021.7009","article-title":"Association of systolic blood pressure with dementia risk and the role of age, U-shaped associations, and mortality","volume":"182","author":"van Dalen","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib55","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210247","article-title":"Association of year-to-year lipid variability with risk of cognitive decline and dementia in community-dwelling older adults","volume":"104","author":"Zhou","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2025.09.1502_bib56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/jnnp.70.1.9","article-title":"Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study","volume":"70","author":"de Leeuw","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jacc.2025.09.1502_bib57","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.neuroimage.2003.12.027","article-title":"The topography of white matter hyperintensities on brain MRI in healthy 60- to 64-year-old individuals","volume":"22","author":"Wen","year":"2004","journal-title":"Neuroimage"},{"key":"10.1016\/j.jacc.2025.09.1502_bib58","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/hbm.20586","article-title":"White matter hyperintensities in the forties: their prevalence and topography in an epidemiological sample aged 44-48","volume":"30","author":"Wen","year":"2009","journal-title":"Hum Brain Mapp"},{"key":"10.1016\/j.jacc.2025.09.1502_bib59","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5853\/jos.2017.02110","article-title":"Prevalence and risk factors of cerebral small vessel disease in a Chinese population-based sample","volume":"20","author":"Han","year":"2018","journal-title":"J Stroke"},{"key":"10.1016\/j.jacc.2025.09.1502_bib60","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Group","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib61","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STR.0000000000000475","article-title":"2024 guideline for the primary prevention of stroke: a guideline from the American Heart Association\/American Stroke Association","volume":"55","author":"Bushnell","year":"2024","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.09.1502_bib62","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.09.1502_bib63","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamaneurol.2023.5456","article-title":"Is incidentally discovered covert cerebrovascular disease ignorable?","volume":"81","author":"Meinel","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib64","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(16)30950-3","article-title":"Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial","volume":"388","author":"Moll van Charante","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.09.1502_bib65","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","article-title":"A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial","volume":"385","author":"Ngandu","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.09.1502_bib66","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1212\/WNL.0000000000003332","article-title":"Aerobic exercise and vascular cognitive impairment: a randomized controlled trial","volume":"87","author":"Liu-Ambrose","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2025.09.1502_bib67","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S1474-4422(17)30040-6","article-title":"Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial","volume":"16","author":"Andrieu","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib68","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41591-024-03351-6","article-title":"An online multidomain lifestyle intervention to prevent cognitive decline in at-risk older adults: a randomized controlled trial","volume":"31","author":"Brodaty","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13195-023-01355-x","article-title":"A multimodal precision-prevention approach combining lifestyle intervention with metformin repurposing to prevent cognitive impairment and disability: the MET-FINGER randomised controlled trial protocol","volume":"16","author":"Barbera","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.jacc.2025.09.1502_bib70","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1212\/WNL.0000000000000884","article-title":"Relation of DASH- and Mediterranean-like dietary patterns to cognitive decline in older persons","volume":"83","author":"Tangney","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2025.09.1502_bib71","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1056\/NEJMoa2302368","article-title":"Trial of the MIND diet for prevention of cognitive decline in older persons","volume":"389","author":"Barnes","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164608","article-title":"Intensive versus guideline blood pressure and lipid lowering in patients with previous stroke: main results from the pilot \u201cPrevention of Decline in Cognition after Stroke Trial\u201d (PODCAST) randomised controlled trial","volume":"12","author":"Bath","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2025.09.1502_bib73","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S1474-4422(08)70198-4","volume":"7","author":"Diener","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib74","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S1474-4422(14)70224-8","article-title":"Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial","volume":"13","author":"Pearce","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib75","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1161\/STROKEAHA.120.032054","article-title":"PRESERVE: randomized trial of intensive versus standard blood pressure control in small vessel disease","volume":"52","author":"Markus","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.09.1502_bib76","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archinte.163.9.1069","article-title":"Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease","volume":"163","author":"Tzourio","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib77","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jamaneurol.2023.1526","article-title":"Isosorbide mononitrate and cilostazol treatment in patients with symptomatic cerebral small vessel disease: the Lacunar Intervention Trial\u20142 (LACI-2) randomized clinical trial","volume":"80","author":"Wardlaw","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib78","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/HYPERTENSIONAHA.120.14993","article-title":"Blood pressure and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 209 prospective studies","volume":"76","author":"Ou","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2025.09.1502_bib79","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209715","article-title":"Blood pressure, antihypertensive use, and late-life Alzheimer and non-Alzheimer dementia risk: an individual participant data meta-analysis","volume":"103","author":"Lennon","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2025.09.1502_bib80","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.09.1502_bib81","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1474-4422(08)70143-1","article-title":"Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial Cognitive Function Assessment (HYVET-COG): a double-blind, placebo controlled trial","volume":"7","author":"Peters","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib82","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","article-title":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)","volume":"265","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.09.1502_bib83","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1001\/archinte.162.18.2046","article-title":"The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study","volume":"162","author":"Forette","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib84","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1093\/eurheartj\/ehac584","article-title":"Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis","volume":"43","author":"Peters","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.09.1502_bib85","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/jama.2018.21442","article-title":"Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial","volume":"321","author":"SPRINT MIND Investigators for the SPRINT Research Group","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.09.1502_bib86","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2004.11.005","article-title":"Differential cognitive outcomes in the Hypertensive Old People in Edinburgh study","volume":"229-230","author":"Starr","year":"2005","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jacc.2025.09.1502_bib87","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithell","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.jacc.2025.09.1502_bib88","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1474-4422(21)00263-5","article-title":"Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer\u2019s disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"20","author":"Kehoe","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002660","article-title":"Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial","volume":"15","author":"Lawlor","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib90","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14443","article-title":"Identifying patients for intensive blood pressure treatment based on cognitive benefit: a secondary analysis of the SPRINT randomized clinical trial","volume":"6","author":"Ghazi","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2025.09.1502_bib91","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jama.2019.10551","article-title":"Association of intensive vs standard blood pressure control with cerebral white matter lesions","volume":"322","author":"SPRINT MIND Investigators for the SPRINT Research Group","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.09.1502_bib92","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1001\/jamaneurol.2021.0178","article-title":"Association of intensive vs standard blood pressure control with magnetic resonance imaging biomarkers of Alzheimer disease: secondary analysis of the SPRINT MIND randomized trial","volume":"78","author":"Nasrallah","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib93","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/HJH.0000000000002621","volume":"39","author":"Scuteri","year":"2021","journal-title":"J Hypertens"},{"key":"10.1016\/j.jacc.2025.09.1502_bib94","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/clc.22147","article-title":"Landmark lipid-lowering trials in the primary prevention of cardiovascular disease","volume":"36","author":"Chrispin","year":"2013","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib95","doi-asserted-by":"crossref","first-page":"e2172","DOI":"10.1212\/WNL.0000000000207876","article-title":"Low- and High-Density Lipoprotein Cholesterol and Dementia Risk Over 17 Years of Follow-up Among Members of a Large Health Care Plan","volume":"101","author":"Ferguson","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2025.09.1502_bib96","article-title":"Statins use and risk of dementia: a dose-response meta analysis","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacc.2025.09.1502_bib97","article-title":"Statins for the treatment of dementia","volume":"2014","author":"McGuinness","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2025.09.1502_bib98","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.09.1502_bib99","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib100","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol : a prespecified analysis of the IMPROVE-IT trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib101","doi-asserted-by":"crossref","first-page":"e1435","DOI":"10.1212\/WNL.0000000000007174","article-title":"Effects of blood pressure and lipid lowering on cognition: results from the HOPE-3 study","volume":"92","author":"Bosch","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2025.09.1502_bib102","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","volume":"57","author":"Hsia","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib103","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.09.1502_bib104","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41440-018-0165-7","article-title":"Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial","volume":"42","author":"Zhang","year":"2019","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jacc.2025.09.1502_bib105","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jamda.2018.05.025","article-title":"Effect of low-dose statins and apolipoprotein e genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial","volume":"19","author":"Ji","year":"2018","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.jacc.2025.09.1502_bib106","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1212\/01.WNL.0000161844.00797.73","article-title":"Effect of pravastatin on cerebral infarcts and white matter lesions","volume":"64","author":"ten Dam","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2025.09.1502_bib107","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1212\/01.wnl.0000182897.18229.ec","article-title":"Statins and cognitive function in the elderly: the Cardiovascular Health Study","volume":"65","author":"Bernick","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2025.09.1502_bib108","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2019.09.041","article-title":"Effects of statins on memory, cognition, and brain volume in the elderly","volume":"74","author":"Samaras","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib109","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/ehjqcco\/qcx037","article-title":"Neurological effects of proprotein convertase subtilisin\/kexin type 9 inhibitors: direct comparisons","volume":"4","author":"Bajaj","year":"2018","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.jacc.2025.09.1502_bib110","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41574-018-0048-7","article-title":"Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications","volume":"14","author":"Biessels","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib111","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3233\/JAD-141521","article-title":"Elevated HbA1c is associated with increased risk of incident dementia in primary care patients","volume":"44","author":"Ramirez","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jacc.2025.09.1502_bib112","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib113","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1474-4422(11)70188-0","article-title":"Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy","volume":"10","author":"Launer","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib114","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Group","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib115","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2337\/dc13-1384","article-title":"Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study","volume":"37","author":"Feinkohl","year":"2014","journal-title":"Diabetes Care"},{"issue":"1 Suppl 1","key":"10.1016\/j.jacc.2025.09.1502_bib116","first-page":"S266","article-title":"Older adults: standards of care in diabetes\u20142025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.09.1502_bib117","doi-asserted-by":"crossref","DOI":"10.3390\/ph15030312","article-title":"Metformin: a narrative review of its potential benefits for cardiovascular disease, cancer and dementia","volume":"15","author":"Top","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jacc.2025.09.1502_bib118","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.2337\/dc20-0892","article-title":"Metformin use is associated with slowed cognitive decline and reduced incident dementia in older adults with type 2 diabetes: the Sydney Memory and Ageing Study","volume":"43","author":"Samaras","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.09.1502_bib119","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1212\/WNL.0000000000004586","article-title":"Metformin vs sulfonylurea use and risk of dementia in US veterans aged \u2265 65 years with diabetes","volume":"89","author":"Orkaby","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2025.09.1502_bib120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3233\/JAD-131901","article-title":"Long-term metformin usage and cognitive function among older adults with diabetes","volume":"41","author":"Ng","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jacc.2025.09.1502_bib121","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212293","article-title":"Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer\u2019s disease: pooled analysis from 5 cohorts","volume":"14","author":"Weinstein","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2025.09.1502_bib122","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3233\/JAD-180263","article-title":"Metformin use associated with reduced risk of dementia in patients with diabetes: a systematic review and meta-analysis","volume":"65","author":"Campbell","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jacc.2025.09.1502_bib123","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib124","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 Receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacc.2025.09.1502_bib125","doi-asserted-by":"crossref","first-page":"T31","DOI":"10.1530\/JOE-13-0221","article-title":"Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases","volume":"221","author":"Holscher","year":"2014","journal-title":"J Endocrinol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib126","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12967-024-04927-z","article-title":"Tirzepatide prevents neurodegeneration through multiple molecular pathways","volume":"22","author":"Fontanella","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101470","article-title":"GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes","volume":"49","author":"Monney","year":"2023","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jacc.2025.09.1502_bib128","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","volume":"8","author":"Norgaard","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.jacc.2025.09.1502_bib129","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","article-title":"Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial","volume":"19","author":"Cukierman-Yaffe","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib130","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib131","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib132","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MED.0000000000000896","article-title":"Interactions between antidiabetes medications and heart-brain axis","volume":"32","author":"Ong","year":"2025","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.jacc.2025.09.1502_bib133","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2337\/dc22-1705","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.09.1502_bib134","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.747620","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset dementia: a propensity score-matched population-based study with competing risk analysis","volume":"8","author":"Mui","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib135","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1111\/jgs.17895","article-title":"Newer glucose-lowering drugs and risk of dementia: a meta-analysis of cardiovascular outcome trials","volume":"70","author":"Tang","year":"2022","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jacc.2025.09.1502_bib136","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/eurheartj\/ehz304","article-title":"Less dementia and stroke in low-risk patients with atrial fibrillation taking oral anticoagulation","volume":"40","author":"Friberg","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.09.1502_bib137","series-title":"Blinded randomized trial of anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation\u2014BRAIN-AF","author":"Rivard","year":"2024"},{"key":"10.1016\/j.jacc.2025.09.1502_bib138","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/j.1540-8167.2011.02035.x","article-title":"Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation","volume":"22","author":"Bunch","year":"2011","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib139","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1111\/jgs.18538","article-title":"Catheter ablation and lower risk of incident dementia and mortality in older adults with atrial fibrillation","volume":"71","author":"Harrison","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jacc.2025.09.1502_bib140","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jocn.2019.12.030","article-title":"Impact of atrial fibrillation burden on cognitive function after left atrial ablation\u2014results of the MACPAF study","volume":"73","author":"Herm","year":"2020","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.jacc.2025.09.1502_bib141","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jacc.2013.03.073","article-title":"Subtle post-procedural cognitive dysfunction after atrial fibrillation ablation","volume":"62","author":"Medi","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib142","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCULATIONAHA.121.055018","article-title":"Atrial fibrillation and dementia: a report from the AF-SCREEN international collaboration","volume":"145","author":"Rivard","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.09.1502_bib143","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","article-title":"Dementia prevention, intervention, and care","volume":"390","author":"Livingston","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.09.1502_bib144","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2318-8-36","article-title":"Smoking, dementia and cognitive decline in the elderly, a systematic review","volume":"8","author":"Peters","year":"2008","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.jacc.2025.09.1502_bib145","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1111\/j.1467-789X.2010.00825.x","article-title":"Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies","volume":"12","author":"Anstey","year":"2011","journal-title":"Obes Rev"},{"key":"10.1016\/j.jacc.2025.09.1502_bib146","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1212\/01.wnl.0000306313.89165.ef","article-title":"Central obesity and increased risk of dementia more than three decades later","volume":"71","author":"Whitmer","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2025.09.1502_bib147","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neurobiolaging.2019.10.005","article-title":"Level of body fat relates to memory decline and interacts with age in its association with hippocampal and subcortical atrophy","volume":"91","author":"Nyberg","year":"2020","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.jacc.2025.09.1502_bib148","doi-asserted-by":"crossref","DOI":"10.1093\/geronb\/gbad184","article-title":"Changes in adiposity and cognitive function in older adults: the REGARDS study","volume":"79","author":"Zhu","year":"2024","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"key":"10.1016\/j.jacc.2025.09.1502_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2023.114228","article-title":"A randomized controlled trial examining the effects of behavioral weight loss treatment on hippocampal volume and neurocognition","volume":"267","author":"Chao","year":"2023","journal-title":"Physiol Behav"},{"key":"10.1016\/j.jacc.2025.09.1502_bib150","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/archinternmed.2010.502","article-title":"Albuminuria and decline in cognitive function: the ONTARGET\/TRANSCEND studies","volume":"171","author":"Barzilay","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib151","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10215175","article-title":"Protective effects of angiotensin receptor blockers on the incidence of dementia in patients with chronic kidney disease: a population-based nationwide study","volume":"10","author":"Chen","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib152","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2025.09.1502_bib153","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2215\/CJN.07440618","article-title":"Blood pressure goals in patients with CKD: a review of evidence and guidelines","volume":"14","author":"Chang","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib154","doi-asserted-by":"crossref","first-page":"ii23","DOI":"10.1093\/ndt\/gfab262","article-title":"Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment","volume":"37","author":"Pepin","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2025.09.1502_bib155","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/j.ajkd.2019.05.017","article-title":"Cognitive Impairment in CKD: pathophysiology, management, and prevention","volume":"74","author":"Drew","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2025.09.1502_bib156","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000444334","article-title":"Cognitive function and white matter changes associated with renal transplantation","volume":"43","author":"Gupta","year":"2016","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib157","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13195-019-0567-z","article-title":"Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCI","volume":"12","author":"Leijenaar","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.jacc.2025.09.1502_bib158","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20198371","article-title":"Oxiracetam ameliorates cognitive deficits in vascular dementia rats by regulating the expression of neuronal apoptosis\/autophagy-related genes associated with the activation of the Akt\/mTOR signaling pathway","volume":"52","author":"Xu","year":"2019","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.jacc.2025.09.1502_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2023.107108","article-title":"Efficacy and safety of oxiracetam in patients with vascular cognitive impairment: a multicenter, randomized, double-blinded, placebo-controlled, phase IV clinical trial","volume":"126","author":"Lim","year":"2023","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jacc.2025.09.1502_bib160","first-page":"417","article-title":"Clinical efficacy and safety of nicergoline combined with oxiracetam in the treatment of vascular cognitive impairment","volume":"33","author":"Wang","year":"2020","journal-title":"Pak J Pharm Sci"},{"key":"10.1016\/j.jacc.2025.09.1502_bib161","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jalz.2009.04.1233","article-title":"Cerebral blood flow in ischemic vascular dementia and Alzheimer\u2019s disease, measured by arterial spin-labeling magnetic resonance imaging","volume":"5","author":"Schuff","year":"2009","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.jacc.2025.09.1502_bib162","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.jacc.2019.04.034","article-title":"Vascular cognitive impairment and dementia: JACC scientific expert panel","volume":"73","author":"Iadecola","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib163","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/alz.12559","article-title":"The PASTIS trial: testing tadalafil for possible use in vascular cognitive impairment","volume":"18","author":"Pauls","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.jacc.2025.09.1502_bib164","article-title":"A multicenter, single-arm, phase II clinical trial of adrenomedullin in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy","volume":"6","author":"Washida","year":"2024","journal-title":"Cereb Circ Cogn Behav"},{"key":"10.1016\/j.jacc.2025.09.1502_bib165","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.993562","article-title":"Daphnetin: a bioactive natural coumarin with diverse therapeutic potentials","volume":"13","author":"Javed","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib166","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1177\/0271678X16658662","article-title":"Reduced global brain metabolism but maintained vascular function in amnestic mild cognitive impairment","volume":"37","author":"Thomas","year":"2017","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.jacc.2025.09.1502_bib167","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1161\/STROKEAHA.116.014321","article-title":"ARTEMIDA trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): a randomized controlled trial to assess the efficacy of actovegin in poststroke cognitive impairment","volume":"48","author":"Guekht","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.09.1502_bib168","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3233\/JAD-210570","article-title":"Cognitive effects of the BET protein inhibitor apabetalone: a prespecified Montreal Cognitive Assessment analysis nested in the BETONMACE randomized controlled trial","volume":"83","author":"Cummings","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jacc.2025.09.1502_bib169","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/STROKEAHA.121.036873","article-title":"Vessels sing their arias: the role of vascular amyloid in the age of aducanumab","volume":"53","author":"Sveikata","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.09.1502_bib170","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.3233\/JAD-210029","article-title":"Photobiomodulation therapy for dementia: a systematic review of pre-clinical and clinical studies","volume":"83","author":"Salehpour","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jacc.2025.09.1502_bib171","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer\u2019s disease combined with cerebrovascular disease: a randomised trial","volume":"359","author":"Erkinjuntti","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.09.1502_bib172","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/01.wnl.0000266625.31615.f6","article-title":"Galantamine treatment of vascular dementia: a randomized trial","volume":"69","author":"Auchus","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2025.09.1502_bib173","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1532-5415.1992.tb03646.x","article-title":"Bedside assessment of executive cognitive impairment: the executive interview","volume":"40","author":"Royall","year":"1992","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jacc.2025.09.1502_bib174","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1007\/s00125-009-1484-7","article-title":"Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial","volume":"52","author":"de Galan","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2025.09.1502_bib175","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00415-009-5271-7","article-title":"Pravastatin and cognitive function in the elderly. results of the PROSPER study","volume":"257","author":"Trompet","year":"2010","journal-title":"J Neurol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib176","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.1502_bib177","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/j.jacc.2020.03.039","article-title":"Cognition after lowering LDL-cholesterol with evolocumab","volume":"75","author":"Gencer","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1502_bib178","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O\u2019Donoghue","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.09.1502_bib179","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.atherosclerosis.2021.06.913","article-title":"Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: a prospective, randomized, placebo-controlled study","volume":"331","author":"Janik","year":"2021","journal-title":"Atherosclerosis"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725093106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725093106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:59:31Z","timestamp":1788307171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725093106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":178,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0735109725093106"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.09.1502","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and Emerging Therapeutic Approaches for Vascular Cognitive Impairment and Dementia","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.09.1502","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.11.008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}